AIMS: To determine the frequencies of the major arylamine- N-acetyltransferase-2 (NAT2) alleles in the Thai population. METHODS: DNA samples from 235 Thai individuals were analysed by polymerase chain reaction with restriction fragment length polymorphism assays. RESULTS: The frequency distribution of major NAT2 alleles, including NAT2*4, NAT2*5, NAT2*6 and NAT2*7 were 0.381 (95% CI 0.337, 0.426), 0.038 (0.023, 0.060), 0.326 (0.283, 0.370) and 0.204 (0.169, 0.244), respectively. When converted to phenotypes, the study population comprised 63.8% rapid acetylators and 36.2% slow acetylators. CONCLUSIONS: The pattern of NAT2 alleles of Thais is similar to those of many Asian populations, although the frequency of NAT2*4 is significantly lower and NAT2*7 is higher than that of Oriental populations.
AIMS: To determine the frequencies of the major arylamine- N-acetyltransferase-2 (NAT2) alleles in the Thai population. METHODS: DNA samples from 235 Thai individuals were analysed by polymerase chain reaction with restriction fragment length polymorphism assays. RESULTS: The frequency distribution of major NAT2 alleles, including NAT2*4, NAT2*5, NAT2*6 and NAT2*7 were 0.381 (95% CI 0.337, 0.426), 0.038 (0.023, 0.060), 0.326 (0.283, 0.370) and 0.204 (0.169, 0.244), respectively. When converted to phenotypes, the study population comprised 63.8% rapid acetylators and 36.2% slow acetylators. CONCLUSIONS: The pattern of NAT2 alleles of Thais is similar to those of many Asian populations, although the frequency of NAT2*4 is significantly lower and NAT2*7 is higher than that of Oriental populations.
Authors: D W Hein; M A Doll; A J Fretland; M A Leff; S J Webb; G H Xiao; U S Devanaboyina; N A Nangju; Y Feng Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-01 Impact factor: 4.254
Authors: D A Bell; J A Taylor; M A Butler; E A Stephens; J Wiest; L H Brubaker; F F Kadlubar; G W Lucier Journal: Carcinogenesis Date: 1993-08 Impact factor: 4.944
Authors: M I Veiga; S Asimus; P E Ferreira; J P Martins; I Cavaco; V Ribeiro; T N Hai; M G Petzold; A Björkman; M Ashton; J P Gil Journal: Eur J Clin Pharmacol Date: 2008-11-01 Impact factor: 2.953